![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-desktop-header-1gif-4289.gif)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-mobgif-81230.gif)
Active Filter(s):
Details:
The collaboration will include co-development of novel precision antibacterials, including first-in-class novel lysins (engineered precision enzymes), targeting indications prone to antimicrobial-resistant infections.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Mayo Clinic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 14, 2024